A5026878273- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Cancer Research and Treatments
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- FOXO transcription factor regulation
- Tryptophan and brain disorders
- Chemical Reactions and Isotopes
- DNA Repair Mechanisms
- Caveolin-1 and cellular processes
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Circular RNAs in diseases
- Cancer-related gene regulation
- Cancer-related Molecular Pathways
- Genomics and Chromatin Dynamics
- Microtubule and mitosis dynamics
- Pancreatic and Hepatic Oncology Research
- Endoplasmic Reticulum Stress and Disease
- Brain Metastases and Treatment
- Mitochondrial Function and Pathology
- Melanoma and MAPK Pathways
Wake Forest University
2025
The Ohio State University
2012-2024
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2009-2024
The Ohio State University Wexner Medical Center
2010-2024
Neurological Surgery
2014
Massachusetts General Hospital
2006-2012
Ohio University
2011
Harvard University
2006-2008
University of Wyoming
2005
Nab-paclitaxel, a nanoparticle conjugate of paclitaxel to human albumin, exhibits efficacy in pancreatic cancer, non-small cell lung cancer and breast cancer. However, there is lack predictive biomarkers identify patients who might benefit most from its administration. This study addresses this gap knowledge by identifying that caveolin-1 (Cav-1) candidate mechanism-based biomarker. Caveolae are small membrane invaginations important for transendothelial albumin uptake. Cav-1, the principal...
FTY720 is a sphingosine analogue that down regulates expression of sphingosine-1-phosphate receptors and causes apoptosis multiple tumor cell types, including glioma cells. This study examined the effect on brain stem cells (BTSCs) derived from human glioblastoma (GBM) tissue. treatment BTSCs led to rapid inactivation ERK MAP kinase, leading upregulation BH3-only protein Bim apoptosis. In combination with temozolomide (TMZ), current standard chemotherapeutic agent for GBM, synergistically...
MicroRNAs regulate several aspects of tumorigenesis and cancer progression. Most tissues are archived formalin-fixed paraffin-embedded (FFPE). While microRNAs a more stable form RNA thought to withstand FFPE-processing degradation there is only limited evidence for the latter assumption. We examined whether microRNA profiling can be successfully conducted on FFPE using SOLiD ligation based sequencing. Tissue storage times (2–9 years) appeared not affect number detected in samples compared...
Purpose: To identify potential molecular hubs that regulate oncogenic kinases and target them to improve treatment outcomes for glioblastoma patients.Experimental Design: Data mining of The Cancer Genome Atlas datasets identified nicotinamide-N-methyl transferase (NNMT) as a prognostic marker glioblastoma, an enzyme linked the reorganization methylome. We tested our hypothesis NNMT plays crucial role by modulating protein methylation, leading inactivation tumor suppressors activation...
Piperlongumine, a natural plant product, kills multiple cancer types with little effect on normal cells. Piperlongumine raises intracellular levels of reactive oxygen species (ROS), phenomenon that may underlie the cancer-cell killing. Although these findings suggest piperlongumine could be useful for treating cancers, mechanism by which drug selectively cells remains unknown.We treated high-grade glioma (HGG) sphere cultures and assessed its effects ROS cell-growth as well changes in...
Abstract Purpose: We employed a metabolomics-based approach with the goal to better understand molecular signatures of glioblastoma cells and tissues, an aim toward identifying potential targetable biomarkers for developing more effective novel therapies. Experimental Design: used liquid chromatography coupled mass spectrometry (LC-MS/Q-TOF LC-MS/QQQ) discovery validation metabolites from primary established cells, normal human astrocytes. Results: identified tryptophan, methionine,...
The repurposing of medications developed for central nervous system (CNS) disorders, possessing favorable safety profiles and blood-brain barrier permeability, represents a promising strategy identifying new therapies to combat glioblastoma (GBM). In this study, we investigated the anti-GBM activity specific antipsychotics antidepressants in vitro vivo. Our results demonstrate that these compounds share common mechanism action GBM, disrupting lysosomal function subsequently inducing membrane...
Inhibitors of murine double minute homolog 2 (MDM2) represent a promising therapeutic approach for the treatment TP53 wild-type glioblastomas (GBMs), reactivating p53 signaling to induce cancer cell death. We conducted surgical window-of-opportunity trial (NCT03107780) MDM2 inhibitor navtemadlin (KRT-232) in 21 patients with recurrent GBM determine achievable drug concentrations within tumor tissues and biological mechanisms response resistance. Participants received at 120 mg ( n = 10) or...
Low‐molecular‐weight organic chromium complexes such as picolinate are often used dietary supplements to improve insulin sensitivity and correct dyslipidemia. However, toxicity associated with compounds has compromised their therapeutic value. The aim of this study was evaluate the impact a newly synthesized complex phenylalanine, Cr(pa) 3 on insulin‐signaling glucose tolerance. by chelating chromium(III) d ‐phenylalanine ligand in aqueous solution. In mouse 3T3‐adipocytes, augmented...
Glioblastoma multiforme (GBM), the most common and aggressive primary brain malignancy, is incurable despite best combination of current cancer therapies. For development more effective therapies, discovery novel candidate tumor drivers urgently needed. Here, we report that peroxiredoxin 4 (PRDX4) a putative driver. PRDX4 levels were highly increased in majority human GBMs as well mouse model GBM. Reducing expression significantly decreased GBM cell growth radiation resistance vitro with...
Abstract Radiotherapy is the standard treatment for glioblastoma (GBM), but overall survival rate radiotherapy treated GBM patients poor. The use of adjuvant and concomitant temozolomide (TMZ) improves outcome; however, effectiveness this varies according to MGMT levels. Herein, we evaluated whether expression affected radioresponse human GBM, stem-like cells (GSCs), melanoma. Our results indicated a correlation between promoter methylation status expression. MGMT-producing cell lines ACPK1,...
Alveolar rhabdomyosarcoma that harbors the PAX3-FOXO1 fusion gene (t-ARMS) is a common and lethal subtype of this childhood malignancy. Improvement in clinical outcomes disease predicated upon identification novel therapeutic targets.Robust mouse models were used for vivo analysis, molecular studies performed on xenografts treated parallel. Two independent patient sets (n = 101 124) clinically annotated tumor specimens analysis FANCD2 levels its association with characteristics outcomes.Our...
Treatment refractory glioblastoma (GBM) remains a major clinical problem globally, and targeted therapies in GBM have not been promising to date. The Cancer Genome Atlas integrative analysis of reported the striking finding genetic alterations p53 PI3K pathways more than 80% GBMs. Given role these making cell-fate decisions responding genotoxic stress, we investigated reliance two mediating radiation resistance. We selected panel cell lines glioma stem cells (GSC) with wild-type TP53...
The goal of this study is to identify and characterize treatment resistant tumor initiating cells (TRTICs) using orthotopic xenografts.TRTICs were enriched from GBM cell lines mouse xenografts treated with fractionated doses radiation temozolomide. TRTICs characterized by neurosphere clonogenicity self-renewal, serial xenotransplantation, differentiation potential, mRNA & miRNA transcriptomic profiling. We use an unbiased approach antigens encoding TRTIC glioma stem (GSC) populations....
Aging | doi:10.18632/aging.100990. Patrick E. Gygli, Joshua C. Chang, Hamza N. Gokozan, Fay P. Catacutan, Theresa A. Schmidt, Behiye Kaya, Mustafa Goksel, Faisal S. Baig, Shannon Chen, Amelie Griveau, Wojciech Michowski, Michael Wong, Kamalakannan Palanichamy, Piotr Sicinski, Randy J. Nelson, Catherine Czeisler, José Otero
Concurrent gemcitabine and nab-paclitaxel treatment is one of the preferred chemotherapy regimens for metastatic locally advanced pancreatic ductal adenocarcinoma (PDAC). Previous studies demonstrate that caveolin-1 (Cav-1) expression critical uptake into tumors correlates with response. Gemcitabine increases by increasing Cav-1 expression. Thus, we hypothesized pretreatment would further enhance sensitivity PDAC to uptake.
// Emily A. Bassett 1 , Kamalakannan Palanichamy Mitchell Pearson Joseph P. McElroy 2 Saikh Jaharul Haque Erica Hlavin Bell and Arnab Chakravarti Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA Center for Biostatistics, Biomedical Informatics, University, Correspondence to: Chakravarti, email: chakravarti.7@osu.edu Keywords: glioblastoma; phospho-proteomic profiling; radiation response; calpastatin; casein kinase Received: December 23,...